PMID- 30509088
OWN - NLM
STAT- MEDLINE
DCOM- 20190815
LR  - 20190815
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 66
IP  - 1
DP  - 2019 Jan 15
TI  - Precise determination of primary cytogenetic abnormalities provides added value 
      for stratification of chronic lymphocytic leukemia patients.
PG  - 128-139
LID - 180201N71 [pii]
LID - 10.4149/neo_2018_180201N71 [doi]
AB  - Cytogenetic analysis has become a standard procedure in the management of newly 
      diagnosed chronic lymphocytic leukemia patients. Prognostic information is 
      reported based on the presence of certain abnormalities and karyotype complexity 
      after conventional karyotyping and/or fluorescence in situ hybridization (FISH). 
      The information on cytogenetic abnormalities occurring in isolation is robust; 
      however, the performance of patients with two or more cytogenetic abnormalities 
      is heterogeneous and information is scarce. This retrospective study analyzed 
      whether information on the precise determination of primary cytogenetic 
      abnormalities can have some added value in terms of risk stratification in 
      chronic lymphocytic leukemia (CLL) patients. The study cohort was 121 patients 
      without the need to start treatment for CLL immediately after diagnosis but had 
      completed initial cytogenetic analysis. Results from conventional karyotyping 
      after stimulation of CLL cells and FISH analysis were combined. Risk 
      stratification based purely on the determination of primary cytogenetic 
      abnormalities was effective in CLL patients, with comparable results in 
      stratification based on the presence of certain abnormalities and karyotype 
      complexity. It is recommended that information on suspected primary abnormalities 
      is included in cytogenetic reports, especially in patients with two or more 
      abnormalities, because this can provide valuable additional information.
FAU - Dvorak, P
AU  - Dvorak P
AD  - Institute of Biology, Faculty of Medicine in Pilsen, Charles University in 
      Prague, Pilsen, Czech Republic.
AD  - Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital 
      Pilsen, Pilsen, Czech Republic.
FAU - Lysak, D
AU  - Lysak D
AD  - Department of Hematology and Oncology, Faculty of Medicine in Pilsen, University 
      Hospital Pilsen, Pilsen, Czech Republic.
AD  - Biomedical Center, Faculty of Medicine in Pilsen, University Hospital Pilsen, 
      Pilsen, Czech Republic.
FAU - Vohradska, P
AU  - Vohradska P
AD  - Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital 
      Pilsen, Pilsen, Czech Republic.
FAU - Subrt, I
AU  - Subrt I
AD  - Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital 
      Pilsen, Pilsen, Czech Republic.
LA  - eng
PT  - Journal Article
DEP - 20180809
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
MH  - *Chromosome Aberrations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/*genetics
MH  - Retrospective Studies
MH  - Risk Assessment
EDAT- 2018/12/05 06:00
MHDA- 2019/08/16 06:00
CRDT- 2018/12/05 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/04/11 00:00 [accepted]
PHST- 2018/12/05 06:00 [pubmed]
PHST- 2019/08/16 06:00 [medline]
PHST- 2018/12/05 06:00 [entrez]
AID - 180201N71 [pii]
AID - 10.4149/neo_2018_180201N71 [doi]
PST - ppublish
SO  - Neoplasma. 2019 Jan 15;66(1):128-139. doi: 10.4149/neo_2018_180201N71. Epub 2018 
      Aug 9.